Other studies have shown that some patients, whose tumours were HER2 negative, show circulating tumour cells (CTCs) that express HER2, and circulating HER2 extracellular domain (ECD) is also found in similar groups of patients (Fehm et al, 2007). Here, ERBB2 is linked to neoplasm.